Response to the Global Stem Cells Group’s practical, hands-on stem cells training course in November paves the way to scheduling more courses in major European cities in 2015
After a successful first run in Spain last month, Global Stem Cells Group, has announced the decision to take the biotech company’s hands-on stem cell training course to additional European cities in 2015. GSCG subsidiary Stem Cell Training, Inc. and Dr. J. Victor Garcia conducted the “Adipose Derived Harvesting, Isolation and Re-integration Training Course” for medical professionals in Barcelona Nov. 22-23, 2014.
The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctor’s office by teaching effective, in-office regenerative medicine techniques.
Global Stem Cells Group will release a schedule of cities and dates for future training classes in upcoming weeks.

The Global Stem Cells Group, Inc. has announced plans to host at least three international symposiums on stem cells and regenerative medicine in Latin America, and one in Miami in 2015.
GlobalStemCellsGroup, Inc. has announced plans to host a minimum of four international symposiums on stem cell research in 2015. The symposiums will be held in three Latin American countries—Chile, Mexico and Colombia—in which Global Stem Cells has established state-of-the-art stem cell clinics staffed with expert medical personnel trained in regenerative medicine, through the StemCell Center.
The fourth symposium will be held in Miami.
The decision follows the success of the Global Stem Cells Group’s first International Symposium on Stem Cells and Regenerative Medicine, held Oct. 2, 3 and 4 in Buenos Aires, Argentina. Global Stem Cells Group CEO Benito Novas says the Buenos Aires event, combined with its steady growth of new clinics throughout Latin America, has provided additional motivation to schedule more stem cell symposiums in an effort to further educate the medical community on the latest advancements in stem cell therapies.
Thanks to Global Stem Cells Group’s growing network of world-class stem cell researchers, treatment practitioners and investors committed to advancing stem cell medicine, the company is rapidly moving closer to its goal of helping physicians to bring treatments into their offices for the benefit of patients.
More than 900 physicians, researchers and regenerative medicine experts from around the world attended the Buenos Aires symposium, and Novas expects that number to grow with upcoming conferences.
“We will continue to bring together a variety of committed stem cell advocates from the U.S., Mexico, Greece, Hong Kong and other regions around the globe, to be joined by a team of knowledgeable speakers, each one presenting the future of regenerative medicine in their field of specialty,” Novas says.
Regenerative medicine as a field is still in its infancy, according to Global Stem Cell Group President and CEO Benito Novas.
“Our objective is to [open a dialogue among the world’s medical and scientific communities in order to advance stem cell technologies and translate them into point of care medicine to the best of out abilities,” Novas says. “Our mission is to bring the benefits of stem cell therapies to the physician’s office safely, efficacy and compliance with the highest standards of care with safety, efficacy and complying with the highest standard of care the world has to offer.
The purpose of each symposium is to bring top stem cell scientists together to share their knowledge and expertise in regenerative medicine, and begin the process of separating myths from facts when it comes to stem cell science and technology.

Stem Cell Training and Bioheart, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Miami in 2015.
Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.

The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices.

Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course is to be held four times in Miami in 2015.

Course details, objectives and instruction include:
Laboratory Training
Hands-On Training
Plating Stem Cells
Harvesting and Freezing stem cells (perform counts and flow)
Gram Stain
Trypan
Mycoplasma
Gowning to enter cleanroom
Flow Cytometry
Endotoxin
Sterility
Environmental monitoring
Calibration and PM
Didactic Lectures will include:
Stem Cell Biology
Cell Culture
Trypsin
Plating
Flow Cytometry
Gram Stain
Trypan
Potency (differentiation)
Cryopreservation
Quality control: endotoxin, sterility, mycoplasma
Gowning to enter cleanroom
Cleanroom Maintenance
Environmental monitoring
Laboratory Protocols

For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-560-5337.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About David B. Harrell, PhD, Brt, OF, FAABRM, FRIPH:
David B. Harrell received his PhD in Molecular Biology, focusing on inter- and intra-cellular communications. Harrell pursued post-doctoral studies at Harvard, Yale, and the University of Rochester and holds national and international awards for his groundbreaking research in signal transduction and cellular communication. Harrell is the owner and chief consultant of Harrell BioScience Consulting, LLC.
Named to Who’s Who in Molecular Biology as well as Public Health and Epidemiology, Harrell is an active reviewer and sits on the editorial boards of several clinical and scientific journals, as well as government agencies. Harrell has several publications in the areas of tissue regeneration, stem cells, neuroscience and epidemiology, and now focuses heavily on translational research. He is a member of the Board of Directors of the American Academy and Board of Regenerative Medicine.

Global Stem Cells Group has announced plans to attend the Vl World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Mexico City, Feb 13, 14 and 15, 2015. Joseph Purita, M.D., head of the Global Stem Cells Group Scientific Advisory Board, will be a keynote speaker.
Joseph Purita, M.D., will represent Global Stem Cells Group, Inc. as a keynote speaker at the VI Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine (A4M) in Mexico City Feb, 13-15, 2015. Purita, who heads the Global Stem Cells Group Scientific Advisory Board, will join other global leaders in the field of anti-aging and regenerative medicine.
Hosted by the American Academy of Anti-aging Medicine (A4M), the conference will be attended by physicians and medical practitioners from different countries and disciplines who will gather to discuss the newest therapies, protocols and innovative procedures available to target health problems associated with old age.
Purita, a pioneer in the use of stem cell therapies in orthopedics, will be joined by Dra Maritza Novas, R.N., M.S.N., a lead trainer and part of the research and development team for Stem Cell Training, Purita and Novas will present the latest advances in evidence-based, best-practice protocols for the early detection, prevention and treatment of medical problems associated with aging.
Global Stem Cells Group plans to host a booth at the conference to present the company’s growing line of regenerative medicine products and services. The event will take place at the Fiesta Americana Reforma Hotel in Mexico City. Attendees will have access to practical and theoretical workshops on a variety of topics related to anti aging medicine, regenerative therapies and cosmetic medicine, and will be able to witness procedures performed by specialists.
Conferences like this one set the standard for medical management and disease treatment for elderly patients.
For more information on the VI Annual World Congress on Anti-Aging Medicine, visit the a4m-mexico website.

The Global Stem Cells Group is joining Argentinian Portal Medestetica to launch Portalstemcells.com to promote education and cutting edge science throughout Spain and Latin America.
GlobalStemCellsGroup.com has announced plans to team with Portal Medestetica, the largest physician portal in Lain America, to launch Portalstemcells.com, a new portal dedicated to providing physicians in Spain and Latin America with relevant information, clinical research news and products relating to stem cells and regenerative medicine.
The new collaboration between Global Stem Cells Group and Portal Medestetica will answer a growing need to expand the reach of high-impact news, studies and breakthroughs, and significantly advance the clinical utilization of stem cell research and clinical trials throughout Latin America. The Portalstemcells.com site is designed to help promote the latest state-of-the-art developments in regenerative medicine as they become available, and to share educational content with physicians throughout the region.
“Portalstemcells.com will be the ideal vehicle to promote education and cutting-edge science throughout the region,” says Ricardo de Cubas, founder of Global Stem Cells Group. “The potential of regenerative medicine and stem cells therapies inspiring the medical community to find real opportunities to repair or replace tissue damaged from disease, relieve pain and provide the potential for curing chronic diseases where no cure existed before.”
The Portalstemcells.com site is aimed at fostering growth and ethical development in the fast-moving field of stem cell medicine by filling a gap in the resources available throughout Latin America. The goal is to elevate the delivery of stem cell science in order to impact the lives of many patients worldwide.

Global leaders in stem cell research and regenerative medicine were in Buenos Aires, Argentina Oct. 2, 3 and 4 for the first ever Global Stem Cells Symposium. The event, hosted by Global Stem Cells Group, presented the top scientific minds from the GSCG faculty.
More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.
The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the world’s most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.
An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:
Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.
Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.
Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cell’s ability to secrete more trophic factors.
According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.
“We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing,” Novas says. “We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physician’s office and I believe we achieved our goals with this symposium.
“Our objective is to open a dialogue among the world’s medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.”
Other experts who spoke to the symposium crowd included:
Maritza Novas, Medical Officer, Global Stem Cells Group, Inc.
Charles F. Mahl, M.D., founder of the Innovative Regenerative Medicine Center in Coral Gables Florida
Global Stem Cells Group is also joining forces with some of the most prestigious regenerative medicine practitioners in South America as it continues to grow its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.

Global Stem Cells Group, Inc., has named neurologist and anti-aging specialist Dra. Mariella Tanzi, founder of BIOMEN S.A, to be the exclusive representative for Global Stem Cells Group in the Costa Rica territory. Tanzi will also open a new Cellgenic clinic in the Costa Rican capital of San Jose.
Global Stem Cells Group, Inc. has signed BIOMEN S.A and its founder, anti-aging and regenerative medicine specialist Dra. Mariella Tanzi, to represent the Miami-based stem cell company as an exclusive representative for the Costa Rican territory. Tanzi will also open a new Cellgenic clinic in the Costa Rican capital of San Jose.
The arrangement is part of the Global Stem Cells Group’s global expansion program, which requires affiliate representatives to have more than five years experience in the health care industry with at least some experience in regenerative medicine.
Tanzi will be instrumental in helping to manage the company’s growth in Costa Rica. Her responsibilities will include arranging a number of stem cell training courses at the Cellgenic facility in Costa Rica over a one-year period, certification of physicians, and willingness to organize an annual stem cell and regenerative medicine symposium in their territory.
“Our main focus is to organize Costa Rica’s first annual symposium on stem cells and regenerative medicine in 2015,” says Global Stem Cells Group Founder Benito Novas. “This new alliance will allow us to establish Cellgenic as a leader in regenerative medicine therapies in Costa Rica.”

Global Stem Cells Group will be represented at the First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia by Maritza Novas, R.N., M.S.N. and Stem Lab Founder Alfredo Hoyos, M.D. Novas and Hoyos are scheduled to speak on non-invasive aesthetic medicine techniques.
Global Stem Cells Group has announced that Alfredo Hoyos, M.D. and Maritza Novas, R.N., M.S.N. will be speaking at the EuroMedicom First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia, Nov. 27, 28 and 29, 2014.
The World Congress Colombia event is organized in cooperation with the International Scientific Board of the AMWC Monaco event, the largest international event in the field of aesthetic and anti-aging medicine. The goal of the event is to showcase the AMWC’s commitment to innovation, expertise and excellence in aesthetic and anti-aging medicine, and to share a wealth of experience and teaching skills with attendees from around the world.
In addition to keeping up with worldwide practices, the Medellin conference is designed to contribute to enhancing practitioners’ skills through advanced academic and clinical sessions, as well as lectures presented by prominent experts in the field like Hoyos and Novas.
Novas and Hoyos will discuss the latest advancements in stem cell medicine for cosmetic and anti-aging applications. Hoyos, founder of Stem Lab, Global Stem Cells Group’s new representative in Colombia, will also discuss plans to hold a symposium on stem cell and regenerative medicine in Bogota in Feb., 2014.
Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary. Hoyos, a prominent Colombian plastic surgeon, is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques. Hoyos will also be promoting the new collaboration between Global Stem Cells Group and his Colombia-based Stem Lab biotechnology company, which develops stem cell techniques for regenerative medicine treatments.
Hoyos serves Global Stem Cells Group and its subsidiary Cellgenic as exclusive representative for the Colombian territory. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket. Five dates are planned for training and physician certification under the Global Stem Cells Group brand in Colombia during 2015.

Global Stem Cells Group, Inc., has signed prominent Colombian plastic surgeon and Stemlab.com founder Alfredo Hoyos, M.D. to represent the Miami-based regenerative medicine company in Colombia.
Global Stem Cells Group, Inc. has signed Stemlab.com founder and prominent plastic surgeon Alfredo Hoyos, M.D. to represent the Miami-based stem cell company as an exclusive representative for the Colombian territory. Hoyos is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques.
Hoyos will join Kristin Comella, Chief Scientific Officer of BioHeart, Inc., to combine his Stemlab medical team with her regenerative medicine protocols to promote research and cutting-edge stem cell technology in Colombia. In addition, Hoyos and Comella will team up in 2005 to provide five stem cell training sessions to medical professionals in Colombia, and establish the country’s first symposium on stem cell therapies and regenerative medicine.
Global Stem Cells Group searches the globe for innovative stem cell practitioners that fit in with the Colombian markets. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.
Cellgenic, Stem Cell Training and Adimarket are regenerative medicine companies under the Global Stem Cells Group brand.
“Our main objective is to organize Colombia’s first symposium on stem cells and regenerative medicine in 2015,” says Global Stem Cells Group Founder Benito Novas. “Our new alliance with Dr. Hoyos and StemLab.com will allow us to establish our brand as the leader in regenerative medicine therapies in Colombia.”
Global Stem Cells Group’s strategy is to expand into foreign markets by recruiting local representatives and distributors like Hoyos to help manage the company’s growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine.
In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.
About Alfredo Hoyos, M.D.:
Colombia-based plastic surgeon Alfredo Hoyos, M.D. takes advantage of his talent as a painter and sculptor to perform high-definition liposculpture, giving his patients athletic-looking bodies with minimal scarring. The creator of high-definition liposculpture and other advanced body contour techniques, Hoyos combines his expertise in regenerative medicine therapies with other technologies to achieve spectacular results in aesthetic and anti-aging medicine.
Hoyos is the founder of Stemlab, a biotechnology company committed to developing new techniques using (stromal) stem cells derived from adipose tissue to improve the quality of life for people.
About BioHeart, Inc.:
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
About Stemlab:
Stemlab is an innovative biotechnology company that aims to fill gaps in the processing and handling of stem cells derived from stromal adipose tissue using the latest technologies in regenerative medicine. The goal is to expand the therapeutic arsenal to increase the options in the treatment of chronic diseases and improve every patient’s quality of life.

Global Stem Cell Group subsidiary Stem Cell Training, Inc. has announced the release of its new online accredited stem cell training course that can be completed from the home or office.
GlobalStemCellsGroup.com, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced a new 16 CME online credit course for physicians. Working at their own pace from the privacy of home or office, physicians can learn how to implement regenerative medicine techniques in their own practices.
Taught by stem cell and regenerative medicine expert Kristin Comella, the online course provides didactic lectures on regenerative medicine and scientifically validated protocols. Lecture topics include:
Stem cell biology
Regulatory environment
Platelet-rich plasma
Induced pluripotent stem cells
cGMPs for stem cell therapies
Embryonic stem cells
Bone Marrow stem cells
Adipose derived stem cells
Harvesting and isolation of adipose derived stem cells
Harvesting and isolation of bone marrow stem cells
Included in the online coursework are training videos, training booklets, detailed protocols and power point presentations with instructions and images for:
Adipose extraction
Adipose stem cell isolation
Bone marrow stem cell isolation
Platelet rich plasma
Patient forms and guidelines (including editable and non-editable confidential medical history for pre- and post-medical instruction, safety guidelines for harvesting adipose tissue, blood work request flyer and confirmation of treatment detailer)
Sample informed consent forms (for adipose derived stem cells, bone marrow derived stem cells and platelet-rich plasma)
Stem Cell Banking with flyers for physicians and patients, as well as stem cell banking requests for cryopreservation
Stem cell training lecture notes
Access to regenerative medicine experts
Medical professionals can also choose to combine the online coursework with one-on-one training with a regenerative medicine specialist.
For more information, visit the Global Stem Cells website,, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
About Kristin Comella:
Kristin Comella has more than 15 years’ experience in corporate entities with expertise in regenerative medicine. Comella has pioneered a variety of stem cell therapies including cord blood derived cells, bone marrow cells, muscle cells and adipose cells for use in many different applications. As Chief Scientific Officer for Bioheart, Inc., Comella has developed a wide range of regenerative products and techniques that have been successfully implemented into the clinic, and has led her team to earn the first ever FDA approval for clinical trials using a combined cell and gene therapy product.
Bioheart is a publicly traded company focusing on the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases. Since joining Bioheart in 2004, Comella has played a major role in managing the product development, manufacturing and quality systems of cellular products. Comella currently and actively serves on multiple boards in the stem cell arena. She joined forces with Global Stem Cells Group and its subsidiary Stem Cells Training in 2013 to design and lead intensive, hands-on stem cell training courses to industry professionals in the U.S. and abroad.